Eric Lefkofsky helped created a company called Tempus because he wanted to make a difference in the field of cancer. The company is helping physicians customize the treatments used for cancer with genomic sequencing. Through their funding for series C, Tempus has raised $70 million. This is a portion of the $130 million raised since the beginning of Tempus in 2015. Eric Lefkofsky is the biggest individual investor for Tempus, and has donated to every fundraising effort. He has stated he is willing to make investments totaling $100 million to Tempus.
Eric Lefkofsky became aware of the hole in the infrastructure for collecting data regarding cancer. Using technology, his can compile the clinical, and genomic data of previous cancer patients. This allows for a more personalized treatment program for physicians. His realization of the lack of data available for oncologists has resulted in a massive database to benefit cancer patients. Partnerships between Tempus, the Cleveland Clinic, the Duke University School of Medicine, and the Mayo Clinic have formed within the last year. This improves the care available for cancer with a library comprised of molecular, and clinical data.
Eric Lefkofsky defines Tempus as a startup in health care, and technology capable of modernizing the treatments available for cancer with a modern infrastructure. Tempus works through Lightbank, a company founded by Eric Lefkofsky, and located in Chicago. Eric Lefkofsky is striving to help physicians make decisions regarding cancer treatments based on the genetic code of the individual patient. These decisions are driven by data, personalized, and reliant on molecular therapies. The genomic analysis, and sequencing used by Tempus reflects the cutting edge of technology.
Eric Lefkofsky’s work has provided physicians with proprietary algorithms, and genomic data, to locate the opportunities to make cancer treatments more precise, and effective. Physicians simply have a better treatment plan, and care opportunities with which to treat their patients. Tempus is currently working with patients with cancer of the lung, breast, and pancreas. Additional types of cancer are expected to be added over time. Tempus employs 29 individuals, and is making progress in their field of expertise.